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Abstract
Inflammation is often a protective reaction against harmful foreign agents. However, in
many disease conditions, the mechanisms behind the inflammatory response are poorly
understood. Often times, the inflammation causes adverse effects, such as joint pain, abdominal
pain, fever, fatigue, and loss of appetite. Thus, many treatments aim to inhibit the inflammatory
response in order to control adverse symptoms. Such treatments include TNFα inhibitors.
However, a major risk associated with drugs inhibiting tumor necrosis factor alpha (TNFα) is
serious infection, including tuberculosis (TB).
Anti-TNFα therapy is used to treat patients with Crohn’s disease, for which the risk of
tuberculosis may be even more concerning. Recent literature suggests Crohn’s might involve
Mycobacterium avium subspecies paratuberculosis (MAP), an intracellular TB-like bacterium.
This study seeks to investigate the risk of developing TB in patients with Crohn’s disease treated
with TNFα inhibitors. A meta-analysis synthesized existing evidence. Evidence came from
published randomized, double-masked, placebo-controlled trials of TNFα inhibitors for treatment
of adult Crohn’s disease.
Twenty-three trials were identified, including 5,669 patients. The risk of tuberculosis was
significantly increased in anti-TNFα treated patients, with a risk difference of 0.028 (95%
confidence interval [CI], 0.0011-0.055). The odds ratio was 4.85 (95% CI, 1.02-22.99) when all
studies were included and 5.85 (95% CI, 1.13-30.38) when studies reporting zero tuberculosis
cases were excluded.
The risk of tuberculosis is increased in patients with Crohn’s disease treated with TNFα
inhibitors. The medical community should be alerted about this risk and the potential for TNFα
inhibitor usage favoring granulomatous infections and worsening the patient condition.
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Introduction
Inflammation is a vital mechanism to protect against foreign agents. However, in many
disease conditions, the immune system reacts for reasons that are not entirely understood. Often
times, the response causes adverse symptoms, as is the case in rheumatoid arthritis, Crohn’s
disease, ankylosing spondylitis, and psoriasis.1 Thus, many treatments aim to inhibit the
inflammatory response in order to control adverse symptoms.2 Such treatments include TNFα
inhibitors. However, a major risk associated with drugs inhibiting tumor necrosis factor alpha
(TNFα) is serious infection, including tuberculosis (TB).3
Anti-TNFα therapy is used to treat patients with Crohn’s disease, for which the risk of
developing TB infection may be even more relevant. Recent literature suggests Crohn’s disease
involves Mycobacterium avium subspecies paratuberculosis (MAP), an intracellular TB-like
bacterium.4-6 Thus, this study seeks to investigate the risk of developing TB in patients with
Crohn’s disease treated with TNFα inhibitors.
Crohn’s disease has become a global disease with a prevalence reaching 0.32% in
Western Europe and North America and an increasing incidence in many other parts of the
world.7 TNFα inhibitors are the recommended therapy to treat moderate to severe Crohn’s
disease, which has led to a rise in the development of biologic therapeutic drugs.8 As of 2018,
three TNFα inhibitors (not including biosimilars) have been approved by the European
Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for treating
patients with Crohn’s disease. These three drugs are adalimumab, certolizumab pegol, and
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infliximab. The aforementioned anti-TNFα therapy have proven efficacy in relieving symptoms
and are play an integral role in treatment options for Crohn’s disease.9,10
However, suppressing the immune system carries many risks. Rare risks, especially, may
not be characterized and studied well in the trials and investigations leading up to drug approval.
Individual double-masked, randomized, placebo-controlled trials (RCTs) of TNFα inhibition
therapy lack the power to analyze and determine whether there are increases in risk for
developing uncommon adverse reactions, such as cancer or serious infection. However, these
RCTs provide quality data for meta-analysis. Indeed, meta-analysis has previously demonstrated
that risk of serious infection was increased for patients suffering from rheumatoid arthritis,
psoriatic arthritis, and ankylosing spondylitis who elected to use TNFα inhibitors to manage their
conditions.3 Furthermore, meta-analysis published in 2016 reported a significantly increased of
opportunistic infections associated with the use of TNFα inhibitors for treatment of Crohn’s
disease. However, the association between tuberculosis or serious infection and anti-TNFα
therapy still remained unclear and was not reported.11 A major limitation to current analytical
methods is the inability to deal with clinical trials reporting zero-event data in both arms of the
studies (“double-zero studies”). Most often, meta-analytical studies excluded these double-zero
studies.12,13 As will be discussed later, the number of aforementioned “double-zero studies” is
high due to the low incidence of tuberculosis. In other scenarios, data from trials with zero-event
data from just one group were often subject to modification (“continuity correction”) that, while
having mathematical basis, lacks biological reasoning. Thus, previous analytical approaches cast
uncertainty about whether or not sufficient evidence indicating an increased risk of developing
TB infection from using TNFα inhibitors is provided.
2

Tuberculosis infection should be provided special attention, as aforementioned, Crohn’s
disease might be caused by Mycobacterium avium subspecies paratuberculosis (MAP).6 TNFα is
of special importance due to its ability to contain granulomatous infections as an inflammatory
cytokine.6 Therefore, TNFα inhibitors can not only to disrupt the human body’s ability to contain
and deal with tuberculosis but also to MAP, further increasing the patient’s susceptibility to the
MAP bacterium or even worsen their disease condition.14 Thus, a meta-analysis of RCTs to
specifically quantify the risk of tuberculosis development in patients who suffer from Crohn’s
disease and were treated with TNFα inhibitors was conducted.
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Background
Concentrations of TNFα have been found to be elevated in the stool, mucosa, and blood
of patients suffering from inflammatory bowel disease. Thus, monoclonal antibodies to TNFα
were synthesized to treat and manage the symptoms of patients.8
Although anti-TNFα therapies have brought great change to the treatment of IBD, there
are theoretical and realized safety concerns. Case reports often initially raise awareness and need
for research regarding novel therapies and their unexpected adverse side effects. Often, it is these
reports that lead to larger powered studies and to hypothesis generation.15
Large scale studies done on TNFα inhibitors as a whole has discovered that the
immunosuppressant therapy does increase patient risk of developing infections and even
cancer.16 Indeed, pharmaceutical companies have funneled large sums of money not only to
conduct clinical trials but to also explore all the possible consequences of biologic medicines.2
Previous studies have found increased risk of tuberculosis, opportunistic infections,
malignancies, and serious infections in various disease groups and over a drug class as a whole.
In fact, adverse events and side effects from the use of biologics are well documented and well
known.14 However, many of these studies are outdated, not comprehensive, or cannot deal with
rare events. Specifically, previous meta-analyses have not investigated whether TNFα inhibitors
increase TB infection risk in patients suffering from Crohn’s disease.12 Up until 2018, there was
not enough literature or lake of tools to investigate such a topic. Previous analyses have been
able to draw conclusions about rheumatoid arthritis and psoriatic disease due to the abundance of
literature. Furthermore, some studies draw counterintuitive results.17 A meta-analysis found that
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there was no increased risk of overall infections in patients suffering from CD where were
treated with TNFα inhibitors versus with placebos.13
With TNFα inhibitors that are approved relatively recently, there are even less studies
and data to draw conclusions from. Conversely, recently approved FDA or EMA drugs
necessitate the greatest amount of scrutiny. These studies often lack the power to draw definitive
assessments, which makes it difficult to come discover and warn the general public of the
potential side effects that the therapies may bring.12
With numerous RCTs of TNFα inhibitors published now, it is possible to draw a more
accurate conclusion and pooled estimate on the risk of TB infection. In addition, a quantified
measurement of risk may be determined.

5

Methods
In an effort to make the data and the work more transparent, this meta-analysis was
registered online in the prospective register of systematic reviews (PROSPERO) international
database on February 8th, 2018 (PROSPERO ID: CRD42018087548).18 The following
methodology adhered closely to the preferred reporting items for systematic reviews and metaanalyses (PRISMA) checklist (Appendix A).19

Data Source and Search Strategy
A database search of PubMed was conducted up until January 21, 2018. The search terms
and methodology used are as follows: biologic(s), tuberculosis, adalimumab, certolizumab,
infliximab, TNFα inhibitors, anti-TNFα, or TNFα in conjunction with Crohn’s disease. The
results were restricted to only double-masked, randomized, placebo-controlled trials.
ClinicalTrials.gov supplemented the search methodology in the event of completed clinical trials
with unpublished data. Studies that were irrelevant were screened out after reviewing the title
and abstracts. Studies that made it past the initial screening had their full text and abstracts
evaluated more closely.

Selection
Only sources written in English were considered. Studies qualified for inclusion if they
were randomized, placebo-controlled, double-masked trials with adequate exposure in adult
populations. Exposure was defined as receiving treatment of TNFα inhibitors (certolizumab
pegol, adalimumab, and infliximab) that were approved for the treatment of adult (18 years or
6

older) Crohn’s disease by the European Medicines Agency and the U.S. Food and Drug
Administration. As mentioned in the introduction, non-approved drugs, including those not in
phase 3 clinical trials, and biosimilars of anti-TNFα therapy were excluded from the metaanalysis. All drug doses were included in the study. Duplicates and observational studies were
screened out. Single studies with both an induction and maintenance phase but reported distinct
patient groups were analyzed as two unique trials.

Data Extraction
Data was extracted onto a Microsoft Excel spreadsheet. First author, year of publication,
study duration, number of participants in treatment and control groups, patient characteristics,
treatment parameters (i.e. TNFα inhibitor and placebo), events in treatment and control groups,
and screening method were recorded from each study. Studies found via ClinicalTrials.gov were
also analyzed, with the aforementioned characteristics also recorded. Cases of TB infection was
the primary outcome assessed in this meta-analysis. TB infection was defined as diagnosis of
active tuberculosis by the clinician or other medical professional participating in the respective
clinical trial.

Risk difference
Arcsine differences (ASD) were used as the measurement of risk differences. For a trial
with 𝑁" subjects in the anti-TNFα treatment group, 𝑁# subjects in the control group, and a and b
(following a standard 2x2 table; table 1) being the number of reported tuberculosis cases,
respectively, the ASD for each individual trial can be calculated with Equation 1:
7

Table 1: Common 2x2 table
Event
Group

Yes

No

Total

Treatment

a

b

nT

Control

c

d

nC

a+c

b+d

n

Total

𝐴𝑆𝐷 = arcsin

(
)*

− arcsin

,
)-

(Equation 1)

The use of arcsine difference for analysis can be dated as far back as the 1940s.20,21 The
notable advantages to using ASD are that the variance of the point estimate (i.e. 𝐴𝑆𝐷) is
determined only by the sample size and that it deals with occurrences of 0 counts naturally,
allowing for trials with 0 events in both arms of the study to be incorporated into metaanalyses.22 A nice graphical representation of arcsine transformation is shown below (figure 1).
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Figure 1: Graphical representation of arcsine difference22

Relative odds
The Yusuf-Peto method calculated odds ratios (ORs).23 Although commonly used, the
Mantel-Haenszel method was not utilized because it cannot include deal with double-zero studies
without substituting zero with a non-zero number. The Yusuf-Peto method provides a distinct
advantage in that it includes single-zero studies; therefore, the Yusuf-Peto odds ratio (𝑂𝑅0123 )
was recognized as a (relatively) more efficient estimator, especially since treatment effects from
trials are not large in number or the size of samples are similar between two groups.24 The
𝑂𝑅0123 for an individual trial was calculated according to Equation 2:

Log𝑂𝑅0123 = (𝑎 − 6(5,
∗ 𝑛 " )*
56
*

-

(6* 56- ); /(6* 56- =>)
(5, 6* =(56- =, 6* 6-

(Equation 2)

where 𝑛 " , 𝑛# , a and b denote the same as in Equation 1.
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However, the Yusuf-Peto method, once again, cannot deal with double-zero studies. As
mentioned previously, known approaches used for meta-analysis on TNFα inhibitors are to
exclude double-zero studies altogether and, in the event of single-zero studies, to change
recorded zero counts by adding either 0.5 events or a number, usually around 0.5 in magnitude,
that calculated based on inverse proportions to the relative size of the opposite drug (treatment or
placebo) group.3,11,25 These analytical treatments lack any basis in biology or epidemiology.

Epidemiologically-Based Background Correction
Through the exclusion of double-zero studies, the obtained results will be biased away
from the null hypothesis. Likewise, a continuity correction may bias the results towards the null.
Thus, an epidemiologically-based background correction (EBC) was proposed and utilized. This
approach estimated an expected number of cases (e.g., if there was an expected 0.01 tuberculosis
case from an experimental arm, such a case would very likely not be observed. However, using
0.01 events to replace a 0 event would more adequately reflect the underlying epidemiology as
opposed to continuity corrections of around 0.5). The epidemiologically-based background
correction assumed an incidence of tuberculosis of 20 cases/100,000 person-years, which was the
incidence reported for patients suffering from inflammatory bowel disease (IBD) in the United
Kingdom.26 EBC was subsequently calculated according to Equation 3 below.

cases
EBC = n × Follow up duration (years)× 100,00020person-years

(Equation 3)

where n equals the number of subjects enrolled in either the treatment or the placebo groups.
10

The mathematics and reasoning behind the correction will be described in the following
statements. The number of people in the control or treatment groups was multiplied by the length
of time of TNFα inhibitor (or placebo) exposure (weeks) to produce exposure length in personweeks. This was converted to person-years by dividing by 54 weeks. The converted exposure
length (person years) was then multiplied by the incidence of TB in the United Kingdom among
populations with inflammatory bowel disease, which was 20 cases/100,000 person years (Aberra
et al., 2007). The end result were cases that were less than 1 but greater than zero. This allowed
for sparse events, such as TB incidence, to be dealt with without using the continuity correction
of 0.5. The EBC was then calculated and added into event counts recording both tuberculosis and
non-tuberculosis for clinical trials with zero event occurrences.

Statistical analysis
Statistical analysis used the intent-to-treat principle. R version 3.4.327, along with the
“meta” package, was utilized to graph plots and calculate the Yusuf-Peto OR and the ASD along
with corresponding confidence intervals (manual calculation on a Microsoft Excel spreadsheet
verified calculation accuracy). Contribution weight from individual studies to the overall, pooled
estimate was calculated based of the inverse variance of the point estimate from individual
studies. The DerSimonian-Laird method calculated inter-study variance28. Two-sided P values of
less than 0.05 with the 95% confidence interval (95% CI) excluding the null was statistically
significant. Plots were recorded and taken using written code (Appendix B).
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Meta-analysis
The beauty of meta-analysis is its ability to pool multiple low-powered studies to increase
the overall power and synthesize data to generate a more conclusive conclusion than single
studies can alone. Such ability to pool data lies heavily in statistics and mathematics. With metaanalysis, two models are primarily followed: fixed-effects and random effects.28 Under the fixedeffects model, population groups across studies are assumed to be relatively similar, with little
variation. Under the random-effects model, populations are assumed to be heterogeneous and
differ from one study to the next.29 In this investigation, the data synthesis will follow the
random-effects model, as study participants were not only in different stands but also in different
countries.
Thus, the overall point estimate, variance, and confidence intervals were calculated. The
overall concept remained similar regardless of which whether the ASD or Yusuf-Peto method
was utilized. Point estimates and variances were generated from each individual study. Weights
were assigned to studies based on an inverse relationship with the respective variance. Thus,
studies that had low numbers of study participants tended to have high variances, which
subsequently lowered their weights. Studies that had many participants had lower variances and,
subsequently, more weight.30
The calculations used for the pooled ASD point estimate are as follows.
For an individual study, k, the 2-arm variance can be estimated as v, where v is
calculated as

v=

>
G6*

+

>
G6-

,

(Equation 4)
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where nT and nC are defined as denoted in table 1.

Assume that there are K studies. For k = 1, . . . , K, the estimated treatment effect
for the kth study is 𝜃k, and the standard error of this particular estimate is sk. The
individual sk is calculated by the following conversion

sk = 𝑣

(Equation 5)

The weight assigned to the estimates from the kth study is denoted by wk =

>
KL;

.

Thus, the overall treatment effect point estimate is provided by

=

P
LQR NL OL
P
LQR NL

,

(Equation 6)

and the standard error, SE, is provided by

SE

=

>
P
LQR NL

.

(Equation 7)

The calculations used for the pooled Yusuf-Peto odds ratio point estimate are as follows.
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For an individual study, k, the variance can be estimated by v, where v is
calculated as
(5S ,5T 6* 6.
6 ; (6=>)

v=

(Equation 8)

and E calculated as
E=

((5S)(,5T)

(Equation 9)
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where a, c, b, d, n, nT, and nC are all defined once again by table 1.
The overall pooled point estimate is subsequently calculated as
ORpeto =

P
LQR((L =UL )
P
LQR VL

,

(Equation 10)

and the standard error, SE, calculated as

SE =

P
LQR VW
P
LQR VW

.

(Equation 11)
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Results
Search Results
From PubMed, a total of 748 articles were located. Titles and abstracts were reviewed to
determine eligibility. Studies that were clearly not relevant, 706 studies in total, to the metaanalysis were excluded. The remaining 42 articles were more closely examined to determine
inclusion in the analysis. Six studies were excluded because they were not head-to-head or
placebo-controlled, 5 did not study FDA or EMA approved drugs, 4 were not placebo-controlled,
and 3 studies were duplicates in that they measured the same sample. All-in-all, 19 of the 42
studies were not included in the analysis. Two additional trials were located through
clinicaltrials.gov; of which, one (NCT00291668) did not post the results and was excluded.
Thus, a total of 23 studies were included in the meta-analysis.16,31-51 The selection process was
summarized in Figure 2 below.
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Figure 2. Evidence collection and selection

The 23 studies evaluated adalimumab (number of studies (n) = 7; 1726 patients),
certolizumab pegol (n = 6; 2008), and infliximab (n = 10; 1935). For this analysis, both induction
and maintenance studies were analyzed. A total of 5669 patients were enrolled in the clinical
trials. Of those enrolled, a total of 3275 patients were in the treatment group and a total of 2394
16

patients were in the control group. The treatment arm sizes were mostly similar to control arm
sizes, with a median ratio being 1.03:1. Nonetheless, some studies had unbalanced arm sizes
(maximum ratio = 3.32:1, average ratio = 1.64:1). Follow-up duration ranged anywhere from 4
to 104 weeks (mean follow-up duration = 32 weeks). A grand total of approximately 79,000
person-years was exposed to either anti-TNFα therapy or placebo throughout the duration of all
the clinical trials (treatment = 46,000 person-years, control = 33,000 in person-years). Dates of
publication ranged from 1997 to 2016. Six cases of tuberculosis were recorded, and all of these
cases were reported in treatment groups. Two cases of TB were recorded in trials using
adalimumab, 1 using certolizumab pegol, and 3 using infliximab. A summary of the trials’
specifics – follow-up duration, treatment, cases, and publication year – is presented in table 2.

Table 2. Summary of randomized, placebo-controlled, double-masked trials included.
N indicated number of total subjects; n indicated number of tuberculosis cases.

Study

Follow-up
Duration (weeks)

Anti-TNFα
Treatment

Placebo

n

N

n

N

Adalimumab
Hanauer et al., 200647

4

0

225

0

74

Colombel et al., 200750

52

2

517

0

261

Sandborn et al., 2007a38

52

0

37

0

18

Sandborn et al., 2007b37

4

0

159

0

166

17

Rutgeerts et al., 201240

48

0

64

0

65

Watanabe et al., 201232

52

0

25

0

25

Watanabe et al., 201232

4

0

67

0

23

Total:

1094

632

Certolizumab Pegol
Winter et al., 200431

12

0

66

0

24

Schreiber et al., 200533

20

0

145

0

73

Sandborn et al., 2007c39

26

0

331

0

329

Schreiber et al., 200734

20

1

216

0

212

Sandborn et al., 201136

6

0

223

0

215

NCT00349752, 201445

36

0

87

0

87

Total:

1068

940

Infliximab
Targan et al., 199716

12

0

83

0

25

D’Haens et al., 199949

4

0

22

0

8

Present et al., 199944

18

0

63

0

31

Rutgeerts et al., 199941

36

0

37

0

36

Hanauer et al., 200248

44

1

385

0

188

18

Sands et al., 200435

40

0

139

0

143

Lémann et al., 200646

52

0

57

0

58

Colombel et al., 201051

30

1

169

0

170

Regueiro et al., 201143

52

0

11

0

13

Regueiro et al., 201642

104

1

147

0

150

Total:

1113

822

Risk Difference
The risk difference between anti-TNFα therapy and placebo was found to be 0.028 (95%
CI, 0.0011-0.055; P < 0.05) (Table 3). The random-effect model results are presented for the
ASD. The fixed effects results for the Peto OR are also presented, although the inter-study
variance did not additionally contribute to the total variance of the pooled OR (the DerSimonianLaird estimate of between study variance was zero).

Table 3. Risk of TB associated with the use of TNFα inhibitors in patients with Crohn’s disease.
N

Risk
estimate

95% Confidence
interval

P

23

0.028

(0.0011, 0.055)

0.042

Including double-zero studies

23

4.85

(1.02, 22.99)

0.047

Excluding double-zero studies

5

5.85

(1.13, 30.38)

0.036

Risk difference
Odds ratio

19

The respective weights for each drug, adalimumab, certolizumab pegol, and infliximab, were
28.9%, 36.9%, and 34.2%. The risk differences were 0.028, 0.015, and 0.042 respectively
(Figure 3).
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Figure 3. Risk difference of tuberculosis infection between patients suffering from
Crohn’s disease treated with TNFα inhibitors and those treated with placebo.

The risk difference was calculated via arcsine transformation of TB infection incidence (Arcus Sinus
Difference, ASD) and was indicated by the numbers on x-axis. Weight indicated the percentage
contribution of the individual study to the pooled estimation. This weight corresponded to the size of the
black box. The x-axis indicated risk difference. Vertical dashed line indicated the pooled point estimate.
Solid horizontal lines described the 95% confidence interval (CI). The solid diamond shows the overall,
pooled confidence interval for each individual TNFα inhibitor and for the entire study.

A funnel plot of the ASDs (Figure 4) was also graphed, indicating that trials that had
smaller risk differences were more often published. However, this does not suggest publication
bias because risk of tuberculosis was neither a reason for publishing the clinical trials nor the
21

primary focus of the studies. To the contrary, the funnel plot showed that larger studies had a
higher likelihood of detecting rare risks (TB infection) than smaller ones.

Figure 4. Relationship between the estimated tuberculosis risk difference and the
corresponding standard error of the estimate.

The center, dashed vertical line indicated the pooled calculated. The diagonal lines indicated the respective
95% confidence intervals associated with the expected mean ASD for clinical trials enrolling a variable
number of study subjects.

Relative odds
The treatment arm sizes were comparable to the control arm sizes. A median ratio of
treatment arm size to control arm size was calculated at 1.03. However, specific studies had
particularly unbalanced arm sizes, with a maximum ratio of 3.32:1 and an average ratio = 1.64:1.
The odds ratio was calculated at 4.85 (95% CI, 1.02-22.99; P<0.05) with the EBC and
5.85 (95% CI, 1.13-30.38; P<0.05) without the EBC (Table 3). The random effects model could
not be used because the Yusuf-Peto odds ratio calculations follows the assumption of a fixed
effects model.23 Weights for adalimumab, certolizumab pegol, and infliximab were 31.1%,

22

18.2%, and 50.7% with EBC, respectively (Figure 5). Without the EBC, only 5 studies could be
included (1 adalimumab trial, 1 certolizumab pegol trial, and 3 infliximab trials).

23

Figure 5. The odds of patients developing active TB infection when treated with TNFα
inhibitors for their Crohn’s disease relative to those treated with placebo.

Odds ratio (OR) was calculated using the Yusuf-Peto method and indicated by the numbers on the x-axis.
Number of tuberculosis infection cases was corrected with a background TB incidence, the EBC. Once
again, the weight was the percentage contribution of an individual study to the pooled estimation. The size
of the black box is proportional to the weight of the study. The vertical dashed line indicated the pooled
odds ratio. The solid horizontal lines show the respective 95% confidence interval (CI). The black diamond
shows the overall confidence interval for each biologic and for the entire analysis.

Number Needed to Harm
With a background TB infection incidence in patients equivalent to 20 cases/100,000 personyears, one active tuberculosis infection case would be expected from a total of 5,000 Crohn’s
disease patients who do not use TNFα inhibitors within one year. An ASD of 0.028 would mean
a tuberculosis incidence of about 177 cases/100,000 person-years; thus, 1 active TB infection
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case would be expected when treating 565 patients with anti-TNFα therapy for one year (Table
4). If the harmful effects of TNFα inhibitors are described on a multiplicative scale, as is the case
with the pooled Yusuf-Peto odds ratio, the numbers of patients treated to expect 1 tuberculosis
case can be anywhere from 855 to 1031 (Table 4).

Table 4. Estimated incidence of active TB infection in patients with Crohn’s disease treated with
anti-TNFα therapy.
Incidence of tuberculosis
Number of patients treated

Based on risk difference

with TNFα treatment

to see one tuberculosis

(cases/person-years)

case in one year

177/100,000

565

97/100,000

1,031

117/100,000

855

Based on relative odds estimated
with background correction
Based on relative odds estimated
without background
correction
The number of patients with Crohn’s disease treated with TNFα inhibitors to expect one active TB infection case is
also shown. The background incidence was assumed to be 20 cases/100,000 person-years.26
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Discussion
Summary
This investigation advances the current state of knowledge on the association between
anti-TNFα therapy and active tuberculosis infection in patients with Crohn’s disease. First, a
non-biased estimation of active tuberculosis infection risk associated with the use of TNFα
inhibitors for the treatment of Crohn’s disease was performed by using arcsine transformations
of tuberculosis infection incidence, which enabled all qualified studies, including double-zero
studies, to be included in the meta-analysis. Secondly, a novel, epidemiologically-based
background correction was developed and used to adjust for zero count events, enabling the
inclusion of double-armed zero event studies into the estimation of the relative effect (odds
ratio). Finally, with the use of the aforementioned analytical approaches, a significant increase of
tuberculosis infection risk with the usage of TNFα inhibitors for the treatment of adult Crohn’s
disease was demonstrated from existing evidence, challenging the findings of previous studies.

Meta-analysis
In this investigation, all qualified clinical trials with public data were included,
amounting to 23 studies in total. Among these 23 studies, 18 (78%) had no reported cases of
tuberculosis infection from either the TNFα inhibitor treatment or the placebo treatment. These
18 studies would have been excluded if the arcsine difference was not used and had the analysis
followed methods that previous meta-analyses regarding this particular area of interest took. The
abundance of double-zero observations was expected. Tuberculosis infection, while a relatively
more common bacterial infection, still qualifies as a rare event in the Americas, Europe, Austria,
26

South Africa, and Japan, which was where these RCTs were conducted. In meta-analysis, a rare
event has less than a 1/1,000 chance of occurrence.29 The median sample size of the control
groups across the 23 studies was 73 people, and the median follow-up duration was 30 weeks.
About 0.0084 tuberculosis cases would be expected, mathematically, in control group if the
background tuberculosis followed the incidence of 20 cases/100,000 person-years as reported by
Aberra et al.26 For reference, if TNFα inhibitors had increased the risk of tuberculosis infection
by 5 times, there would be about a 4% chance to observe 1 event in the anti-TNFα treatment
arm. Meta-analysis provides the ability and opportunity to pool multiple studies together to
increase the probability of observing a single tuberculosis infection case. Furthermore,
discarding double-zero studies (78% of the studies in our analysis) might decrease the value of
meta-analysis.
The risk difference calculated using the arcsine transformation of incidence was
considered as the primary results. The ASD method does not need any correction for zero-event
counts. Additionally, the ASD estimate provides another advantage in that it is not contingent on
the effect size or the balance of sample sizes between the treatment and control groups. These
analytical features greater utility over either the Yusuf-Peto method or the Mantel-Haenszel
method. However, a more intuitive understanding of risk of TB infection may be better described
on a multiplicative scale as a ratio. Thus, further analysis was performed, for which the YusufPeto method was the approach of choice because, compared to the Mantel-Haenszel method, it
can handle zero events in single arms.52 Even with non-zero events, the Mantel-Haenszel method
lacks sufficient power and can be substantially worse than other statistical methods when
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occurances are less that 1 in 1,000.53 Unfortunately, the Yusuf-Peto method cannot handle
double-zero studies.

Funnel Plot
A funnel plot graphing ASDs of the studies (figure 3) versus their standard errors was
relatively symmetric and followed an inverted funnel shape, showing a low risk of publication
bias, selective outcome reporting, or selective analysis reporting (Egger et al., 1997). However, it
is still unclear if funnel plots really diagnose publication bias (Lau et al., 2006). Since risk of TB
was not the primary reason the clinical trials were conducted, it is more likely that publication
bias is less of a concern.

Epidemiological Background Correction
An epidemiologically based background correction (i.e., EBC) was proposed in order to
mathematically replace zero events. The formula to calculate the corrections was based off the
exposure length (person-years) and the UK TB incidence rate in IBD populations to produce a
non-zero number of TB cases. In the event that metrics other than ASD (i.e. odds ratio, hazards
ratio or rate ratio) are estimated and that the event of interest is so rare that even one occurrence
would not be expected, the EBC is recommended for continuity corrections instead of adding
0.5, similar corrections based on the ratio of the sample size between treatment and control
groups, or statistical-model based estimates.29,30 The latter approaches are not rooted in
epidemiology and lack biological considerations. In the case of adding 0.5 or a similar modifier,
the correction artificially makes a much larger background incidence than there actually is. For
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example, in this study, it would have boosted the background incidence by about a factor of 60.
Thus, the common artificial continuity correction was not used was due to its inaccuracy and
invalid conclusion regarding small sample size, small number of studies, or low event rates.52

Limitations
All data from all clinical trials were assumed to be available and that no bias due to
unpromising results not being reported or due to patient withdrawals were present. Additionally,
if a study did not report TB outcomes, then it was assumed that that there were 0 cases of TB in
that study. The FDA mandates that serious infections are reported in clinical trials, which TB is
defined as54. However, it is possible that cases of TB were reported under serious infections or
opportunistic infections without being reported in the study.
There are some notable limitations with the use of the EBC. The EBC was based on the
tuberculosis incidence rate in the UK IBD populations up until 1997, before the first TNFα
inhibitors were available to the public. In the decades since then, it is possible that TB incidences
in these UK populations have changed. The reported incidence also takes into account that the
Crohn’s patients likely used certain medications that increased their risk of infection overall,
such as corticosteroids. Additionally, although most of the studies were conducted in Western
countries, the TB infection incidence of Crohn’s patients in the United Kingdom may also not
truly represent the average TB infection incidence of the countries in which the clinical trials
were conducted. Furthermore, the TB infection incidence rate was that found in populations with
IBD overall, which may not be representative of TB infection incidence in populations with
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Crohn’s disease. Since the correction assumed the incidence of TB is identical with or without
TNFα inhibitor usage in the clinical trials, the results are also biased towards the null.
In the TB incidence is closer to that found in the general population in the UK, which is 9
cases/100,000 person-years, then the double-zero studies included in the meta-analysis would
have a lower calculated weight.26 That would result in the five studies with reported cases of TB
infection having a higher contribution to the pooled estimate, leading to an overall ratio that is
higher (closer to the 8.85 times increased risk) with a larger confidence interval than the Peto OR
calculated with the determined correction but smaller than the Peto OR calculated without the
double-zero studies.
Aside from the approaches to avoid Simpson’s paradox, the ability to pool distinct results
from individual clinical trials in this meta-analysis resided in the fact that each study had a
placebo-treatment arm. Therefore, the impact from having different study populations was
largely minimized, as either the end point (risk difference or odds ratio) mostly reflected the
effect of TNFα inhibitors alone (the impact of confounders was either subtracted out [for ASD]
or divided out [for ORs]). Thus, between-study heterogeneity such as geographic location,
population characteristics, exposure, maintenance vs. induction trials, and screening methods is
assumed to be minimized. Within study heterogeneity such as age, geographic location,
exposure, and race is assumed to be reduced by the random assignment of participants to
treatment and control groups.
All the studies were in English, so the generalizability of the results may be limited,
especially considering that the demographics and trends of both Crohn’s disease and tuberculosis
infection differ between western and eastern countries.55 The included studies were also mainly
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EMA- and FDA-regulated clinical trials conducted in western countries. In fact, only one study
that enrolled largely Asian populations was included in this meta-analysis.32 In this regard, EBC
may also be compromised, since the prevalence and incidence of tuberculosis is higher in Asian
countries.56 Thus, much caution should be taken when extrapolating and applying results from
this analysis to predict TB infection risk of using anti-TNFα therapy to treat Crohn’s disease in
non-western countries.

Screening
Special attention should be paid to screening. Patients could have had either latent TB
infection that was reactivated or acquired TB infection through exposure. The screening methods
varied by trial and often went unreported. Additionally, screening out patients based on a
positive tuberculin skin test may bias certain patient population groups due to the prevalence of
BCG vaccinations in non-western countries. Furthermore, screening out patients based on a
positive tuberculin skin test may have different impacts on the tuberculosis occurrence due to the
different practices of Bacillus Calmette-Guérin vaccinations.57 Thus, certain study groups may
have less immigrant participants enrolled. That would therefore lower the expected number of
TB infection cases. Finally, two studies did not report screening methods.42,48 Closer
examination of the details of trial screenings may provide additional insight on the nature of TB
infection – whether it is acquired or reactivated.
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Future Research
Much still remains uncertain about the etiology Crohn’s disease. Current literature
suggests that Crohn’s disease might be caused by an immune response to enteric bacteria.58
Recent research also points to Crohn’s disease being intimately linked with MAP, a TB-like
bacterium.6 The use of anti-TNFa therapy in these patients could even favor MAP infection and
worsen the patient condition, which is what was found in this study. Currently, it is difficult to
come to conclusions about possible linkages, considering that the RCTs did screen or test for
MAP infection – much less reported it. Additional research could be done on analyzing patient
outcomes and determining which patients were infected with MAP and their susceptibility to
overall, serious, or TB infection was.
Much more research could be done on the EBC. Specifically, mathematically modeling to
determining the validity of such a correction as compared to previous existing methodologies
would elucidate the strengths and weaknesses of such an approach. This is not the first time a
novel correction was introduced. In a 2016 study, Bai et al. used a similar correction that could
adjust for zero outcomes when events are rare.30 Thus, more needs to be elucidated on the current
meta-analytical approaches, tools, and corrections so that data from clinical trials can be more
adequately assessed.
Additional models can be explored as an avenue to analyze rare event data. The betabinomial model holds much promise; however, its programming and transformations can be
difficult to interpret.21 Nonetheless, future research and analyses could explore and investigate
the pros and cons to using the beta-binomial method.
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Finally, future meta-analysis could analyze other adverse events reported by clinical
trials. Such topics of interest include risk of serious infection and overall infection. The topic of
interest could be extended or narrowed. For example, further analysis could be done on antiTNFα therapy as a whole or study pediatric subpopulations.
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Conclusion
All in all, this study concluded that there is sufficient evidence to support the association
between TNFα inhibitors use and an increased the risk of developing tuberculosis in patients
with Crohn’s disease. Twenty-three studies were analyzed with multiple statistical methods
consistently providing significant risk. To current knowledge, all these 23 studies represent the
most comprehensive and appropriate literature available for the topic at hand, with an extensive
search and careful review conducted. No studies written in English were excluded, provided that
a placebo control was present and that they were randomized and masked. The randomization of
patients and clinicians minimized potential confounding agents such as age, duration of IBD, and
disease activity.
The results challenge findings from previous studies, which all reported no significantly
increased risk of tuberculosis infection associated with TNFα inhibitor usage among patients
with Crohn’s disease.11,13 Based on the pooled risk difference (ASD) calculated in this study, on
average 565 patients treated with TNFα inhibitors would be expected to result in 1 patient getting
infected with TB, versus 5000 patients electing therapy other than TNFα inhibitors producing 1
case of TB, assuming the background incidence of tuberculosis in moderately severe Crohn’s
disease is similar to the reported rates in the UK IBD population.
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Appendix A: PRISMA Checklist for Meta-Analysis
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Appendix B: R Code for Plot and Image Generation
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Appendix B-1: Arcsine R Code (forest plot and funnel plot)
dat<-read.csv(file="<file location>", header=TRUE, sep=","); dat;
CD <- metabin(event.e=ai, n.e=n1, event.c=ci, n.c=n2, data = dat, sm = "ASD", byvar=Drug,
studlab=paste(Authors), print.byvar=FALSE); CD;

pdf(file = "<file location/figure name.pdf>", width = 8.5, height = 11);
forest(CD, leftcols=c("studlab"), comb.fixed=FALSE, hetstat =FALSE, digits=4,
col.by="black", col.diamond="black", col.square="black"); dev.off();

jpeg(file=""<file location/figure name.jpeg>", width = 10, height = 10, units = 'in', res = 600);
forest(CD, leftcols=c("studlab"), comb.fixed=FALSE, hetstat =FALSE, digits=4,
col.by="black", col.diamond="black", col.square="black"); dev.off();

tiff(file="<file location/figure name.tiff>", width = 10, height = 10, units = 'in', res = 600);
forest(CD, leftcols=c("studlab"), comb.fixed=FALSE, hetstat =FALSE, digits=4,
col.by="black", col.diamond="black", col.square="black"); dev.off();

jpeg(file="<file location/figure name_funnel.jpeg>", width = 10, height = 8, units = 'in', res =
600);
38

par(ps = 13, cex = 1.5, cex.main = 1); funnel(CD, bg="black", axes=FALSE); axis(1, at=seq(0.4, 0.5, 0.1)); axis(2); dev.off();
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Appendix B-2: Yusuf-Peto R Code (forest plot)
dat<-read.csv(file="<file location>","); dat;
CD <- metabin(event.e=ai, n.e=n1, event.c=ci, n.c=n2, data = dat, sm = "OR", method = "Peto",
byvar=Drug, studlab=paste(Authors), print.byvar=FALSE); CD;
pdf(file = "<file location/figure name.pdf>", width = 8.5, height = 11);
forest(CD, comb.random=FALSE, hetstat =FALSE, col.by="black", col.diamond="black",
col.square="black", rightcols=c("w.fixed"), xlim=c(0.01, 400), colgap="4mm", digits.weight=3);
dev.off();

jpeg(file=""<file location/figure name.jpeg> ",
width = 10, height = 10, units = 'in', res = 600);
forest(CD, comb.random=FALSE, hetstat =FALSE, col.by="black", col.diamond="black",
col.square="black", rightcols=c("w.fixed"), xlim=c(0.01, 400), colgap="4mm", digits.weight=3);
dev.off();

tiff(file="<file location/figure name.tiff>", width = 10, height = 10, units = 'in', res = 600);
forest(CD, comb.random=FALSE, hetstat =FALSE, col.by="black", col.diamond="black",
col.square="black", rightcols=c("w.fixed"), xlim=c(0.01, 400), colgap="4mm", digits.weight=3);
dev.off().

40

References
1.

Clarke K, Chintanaboina J. Allergic and immunologic perspectives of inflammatory
bowel disease. Clinical reviews in allergy & immunology 2018.

2.

Fernandes JC. Therapeutic application of antibody fragments in autoimmune diseases:
Current state and prospects. Drug discovery today 2018.

3.

Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-tnf agents in
rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review
and meta-analysis. Expert Opin Drug Saf 2016;15:11-34.

4.

Naser SA, Thanigachalam S, Dow CT, Collins MT. Exploring the role of mycobacterium
avium subspecies paratuberculosis in the pathogenesis of type 1 diabetes mellitus: A pilot
study. Gut pathogens 2013;5:14.

5.

Naser SA, Schwartz D, Shafran I. Isolation of mycobacterium avium subsp
paratuberculosis from breast milk of crohn's disease patients. The American journal of
gastroenterology 2000;95:1094-5.

6.

Naser SA, Sagramsingh SR, Naser AS, Thanigachalam S. Mycobacterium avium
subspecies paratuberculosis causes crohn's disease in some inflammatory bowel disease
patients. World journal of gastroenterology 2014;20:7403-15.

7.

Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory
bowel disease in the 21st century: A systematic review of population-based studies.
Lancet (London, England) 2018;390:2769-78.

41

8.

Swaminath A, Lebwohl B, Capiak KM, Present DH. Practice patterns in the use of antitumor necrosis factor alpha agents in the management of crohn's disease: A us national
practice survey comparing experts and non-experts. Dig Dis Sci 2011;56:1160-4.

9.

Sultan S, Falck-Ytter Y, Inadomi JM. The aga institute process for developing clinical
practice guidelines part one: Grading the evidence. Clinical gastroenterology and
hepatology : the official clinical practice journal of the American Gastroenterological
Association 2013;11:329-32.

10.

Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American
gastroenterological association institute technical review on the use of thiopurines,
methotrexate, and anti-tnf-alpha biologic drugs for the induction and maintenance of
remission in inflammatory crohn's disease. Gastroenterology 2013;145:1464-78.e1-5.

11.

Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and
malignancy in patients with inflammatory bowel disease: A systematic review and
network meta-analysis. Clinical gastroenterology and hepatology : the official clinical
practice journal of the American Gastroenterological Association 2016;14:1385-97.e10.

12.

Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis:
Malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel
disease. Aliment Pharmacol Ther 2014;39:447-58.

13.

Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factoralpha therapy in inflammatory bowel disease: Meta-analysis of randomized controlled
trials. The American journal of gastroenterology 2013;108:1268-76.

42

14.

Qasem A, Naser AE, Naser SA. The alternate effects of anti-tnfalpha therapeutics and
their role in mycobacterial granulomatous infection in crohn's disease. Expert Rev Anti
Infect Ther 2017;15:637-43.

15.

Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor
necrosis factor alpha-neutralizing agent. The New England journal of medicine
2001;345:1098-104.

16.

Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric
monoclonal antibody ca2 to tumor necrosis factor alpha for crohn's disease. Crohn's
disease ca2 study group. The New England journal of medicine 1997;337:1029-35.

17.

Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-tnfalpha therapy among patients with rheumatoid arthritis: Results from the british society
for rheumatology biologics register. Rheumatology (Oxford, England) 2006;45:1558-65.

18.

Cao B, Naser SA. Systematic review and meta-analysis on the risk of tuberculosis in
patients with crohn's disease who take tnfα inhibitors. PROSPERO: PROSPERO:
International prospective register of systematic reviews, 2018.

19.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic
reviews and meta-analyses: The prisma statement. BMJ (Clinical research ed)
2009;339:b2535.

20.

Freeman M, Tukey J. Transformations related to the angular and the square root. Annals
of Mathematical Statistics 1950;21:607-11.

21.

Anscombe FJ. The transformation of poisson, binomial and negative-binomial data.
Biometrika 1948;35:246-54.
43

22.

Rucker G, Schwarzer G, Carpenter J, Olkin I. Why add anything to nothing? The arcsine
difference as a measure of treatment effect in meta-analysis with zero cells. Statistics in
medicine 2009;28:721-38.

23.

Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after
myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis
1985;27:335-71.

24.

Brockhaus AC, Bender R, Skipka G. The peto odds ratio viewed as a new effect measure.
Statistics in medicine 2014;33:4861-74.

25.

Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-tnf antibody therapy in rheumatoid
arthritis and the risk of serious infections and malignancies: Systematic review and metaanalysis of rare harmful effects in randomized controlled trials. Jama 2006;295:2275-85.

26.

Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Risk for active
tuberculosis in inflammatory bowel disease patients. Clinical gastroenterology and
hepatology : the official clinical practice journal of the American Gastroenterological
Association 2007;5:1070-5.

27.

R Core Team. R: A language and environment for statistical computing. R foundation for
statistical computing, vienna, austria. Url http://www.r-project.org/. 2017.

28.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:17788.

29.

Bhaumik DK, Amatya A, Normand SL, et al. Meta-analysis of rare binary adverse event
data. Journal of the American Statistical Association 2012;107:555-67.

44

30.

Bai O, Chen M, Wang X. Bayesian estimation and testing in random effects metaanalysis of rare binary adverse events. Statistics in biopharmaceutical research
2016;8:49-59.

31.

Winter TA, Wright J, Ghosh S, et al. Intravenous cdp870, a pegylated fab' fragment of a
humanized antitumour necrosis factor antibody, in patients with moderate-to-severe
crohn's disease: An exploratory study. Aliment Pharmacol Ther 2004;20:1337-46.

32.

Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance
of clinical remission in japanese patients with crohn's disease. J Crohns Colitis
2012;6:160-73.

33.

Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of
certolizumab pegol (cdp870) for treatment of crohn's disease. Gastroenterology
2005;129:807-18.

34.

Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with
certolizumab pegol for crohn's disease. The New England journal of medicine
2007;357:239-50.

35.

Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for
fistulizing crohn's disease. The New England journal of medicine 2004;350:876-85.

36.

Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active crohn's
disease: A placebo-controlled, randomized trial. Clinical gastroenterology and
hepatology : the official clinical practice journal of the American Gastroenterological
Association 2011;9:670-8.e3.

45

37.

Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for crohn
disease previously treated with infliximab: A randomized trial. Ann Intern Med
2007;146:829-38.

38.

Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of
crohn's disease: Results of the classic ii trial. Gut 2007;56:1232-9.

39.

Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of
crohn's disease. The New England journal of medicine 2007;357:228-38.

40.

Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains
mucosal healing in patients with crohn's disease: Data from the extend trial.
Gastroenterology 2012;142:1102-11.e2.

41.

Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in crohn's disease.
Gastroenterology 1999;117:761-9.

42.

Regueiro M, Feagan BG, Zou B, et al. Infliximab reduces endoscopic, but not clinical,
recurrence of crohn's disease after ileocolonic resection. Gastroenterology
2016;150:1568-78.

43.

Regueiro M, El-Hachem S, Kip KE, et al. Postoperative infliximab is not associated with
an increase in adverse events in crohn's disease. Dig Dis Sci 2011;56:3610-5.

44.

Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in
patients with crohn's disease. The New England journal of medicine 1999;340:1398-405.

46

45.

UCB Pharma. Corticosteroid sparing effect of certolizumab in crohn's disease (cospar1)
(nct00349752; last update posted on september 5, 2014). Available at clinicaltrials.Gov.
Accessed on march 27, 2018.

46.

Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent
crohn's disease patients: A randomized placebo-controlled trial. Gastroenterology
2006;130:1054-61.

47.

Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor
monoclonal antibody (adalimumab) in crohn's disease: The classic-i trial.
Gastroenterology 2006;130:323-33; quiz 591.

48.

Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for crohn's
disease: The accent i randomised trial. Lancet (London, England) 2002;359:1541-9.

49.

D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing
with infliximab anti-tumor necrosis factor antibodies in crohn's disease: A european
multicenter trial. Gastroenterology 1999;116:1029-34.

50.

Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical
response and remission in patients with crohn's disease: The charm trial.
Gastroenterology 2007;132:52-65.

51.

Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination
therapy for crohn's disease. The New England journal of medicine 2010;362:1383-95.

52.

Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: A
comparison of the performance of meta-analytical methods with rare events. Statistics in
medicine 2007;26:53-77.
47

53.

Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. The New England journal of medicine
2018;378:1277-90.

54.

Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with
polyarticular-course juvenile idiopathic arthritis: Results from a phase 3, randomised,
double-blind withdrawal trial. Ann Rheum Dis 2015;74:1110-7.

55.

Ng SC. Emerging trends of inflammatory bowel disease in asia. Gastroenterology &
hepatology 2016;12:193-6.

56.

WHO. Global tuberculosis report 2017. Available at
http://www.who.int/tb/publications/global_report/en/. Accessed on march 27, 2018.

57.

Zwerling A, Behr MA, Verma A, et al. The bcg world atlas: A database of global bcg
vaccination policies and practices. PLoS Med 2011;8:e1001012.

58.

Sartor RB. Mechanisms of disease: Pathogenesis of crohn's disease and ulcerative colitis.
Nature clinical practice Gastroenterology & hepatology 2006;3:390-407.

48

